Patents by Inventor Athanasios Dousis

Athanasios Dousis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE FOR THE TREATMENT OF PHENYLKETONURIA
    Publication number: 20210040456
    Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.
    Type: Application
    Filed: November 21, 2018
    Publication date: February 11, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Raj Rajendran, Patrick Finn, Paolo G.V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
  • POLYNUCLEOTIDES ENCODING RELAXIN
    Publication number: 20200354429
    Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 12, 2020
    Applicant: MODERNATX, INC.
    Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • Polynucleotides encoding relaxin
    Patent number: 10730924
    Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 4, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • RNA POLYMERASE VARIANTS
    Publication number: 20200131550
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • RNA polymerase variants
    Patent number: 10526629
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • In vitro transcription methods and constructs
    Patent number: 10465190
    Abstract: The present disclosure provides, in some aspects, in vitro transcription systems (including, for example, nucleic acid constructs and polymerases), the use of which increases transcription efficiency while reducing the amount of truncated single-stranded ribonucleic acid transcript produced during an in vitro transcription reaction.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 5, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Jesse Chen, Athanasios Dousis
  • RNA POLYMERASE VARIANTS
    Publication number: 20190309337
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 10, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • POLYNUCLEOTIDES ENCODING RELAXIN
    Publication number: 20180371047
    Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
    Type: Application
    Filed: July 2, 2018
    Publication date: December 27, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe